← board
EVOTF
distress 0/10 · well-funded / low risk$6.690%today-22% from 52w high
Revenue
$157M
Liquidity
$517M
Runway
56.3 yrs
Shares 1y
0%
Price & events
-16.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
+0.0%
1W
+0.0%
1M
+27.7%
3M
-16.5%
6M
-21.4%
1Y
-34.0%
2Y
-84.6%
5Y
-80.4%
All
Overview
- Market Cap
- $1.19B
- Enterprise Value
- $1.10B
- Volume
- 0
- 52 Week Range
- $4.72 – $8.58
- Total Shares
- 177.78M
- Float Shares
- 133.41M
- % Held by Insiders
- 9.97%
- % Held by Institutions
- 67.32%
- Beta
- 1.31
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-13earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 177,778,907 · 0 offerings/1y · 0 PIPEs
- 2024-11-08SC 13Dstrategic_stake
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.